Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v52,p223)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stitt, A.
Right arrow Articles by Thorpe, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stitt, A.
Right arrow Articles by Thorpe, S. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2826-2832, 2002
© 2002 by the American Diabetes Association, Inc.

The AGE Inhibitor Pyridoxamine Inhibits Development of Retinopathy in Experimental Diabetes

Alan Stitt1, Thomas A. Gardiner1, Nathan L. Anderson2, Paul Canning1, Norma Frizzell1, Noel Duffy1, Cliona Boyle1, Andrzej S. Januszewski2, Mark Chachich2, John W. Baynes2, and Suzanne R. Thorpe2

1 Department of Ophthalmology, Institute of Clinical Science, The Royal Victoria Hospital, Queen’s University of Belfast, Belfast, Northern Ireland
2 Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina

We examined the ability of pyridoxamine (PM), an inhibitor of formation of advanced glycation end products (AGEs) and lipoxidation end products (ALEs), to protect against diabetes-induced retinal vascular lesions. The effects of PM were compared with the antioxidants vitamin E (VE) and R-{alpha}-lipoic acid (LA) in streptozotocin-induced diabetic rats. Animals were given either PM (1 g/l drinking water), VE (2,000 IU/kg diet), or LA (0.05%/kg diet). After 29 weeks of diabetes, retinas were examined for pathogenic changes, alterations in extracellular matrix (ECM) gene expression, and accumulation of the immunoreactive AGE/ALE N{varepsilon}-(carboxymethyl)lysine (CML). Acellular capillaries were increased more than threefold, accompanied by significant upregulation of laminin immunoreactivity in the retinal microvasculature. Diabetes also increased mRNA expression for fibronectin (2-fold), collagen IV (1.6-fold), and laminin ß chain (2.6-fold) in untreated diabetic rats compared with nondiabetic rats. PM treatment protected against capillary drop-out and limited laminin protein upregulation and ECM mRNA expression and the increase in CML in the retinal vasculature. VE and LA failed to protect against retinal capillary closure and had inconsistent effects on diabetes-related upregulation of ECM mRNAs. These results indicate that the AGE/ALE inhibitor PM protected against a range of pathological changes in the diabetic retina and may be useful for treating diabetic retinopathy.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
X. Fan and V. M. Monnier
Inhibition of Crystallin Ascorbylation by Nucleophilic Compounds in the hSVCT2 Mouse Model of Lenticular Aging
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4945 - 4952.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S.-Y. Goh and M. E. Cooper
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A Bhatwadekar, J V Glenn, J L Figarola, S Scott, T A Gardiner, S Rahbar, and A W Stitt
A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats
Br. J. Ophthalmol., April 1, 2008; 92(4): 545 - 547.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. V. Glenn, J. R. Beattie, L. Barrett, N. Frizzell, S. R. Thorpe, M. E Boulton, J. J. McGarvey, and A. W. Stitt
Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging
FASEB J, November 1, 2007; 21(13): 3542 - 3552.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Nakamura, H. Li, A. Adijiang, M. Pischetsrieder, and T. Niwa
Pyridoxal phosphate prevents progression of diabetic nephropathy
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2165 - 2174.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Sugimoto, G. Grahovac, M. Zeisberg, and R. Kalluri
Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors
Diabetes, July 1, 2007; 56(7): 1825 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
G. Tezel, C. Luo, and X. Yang
Accelerated Aging in Glaucoma: Immunohistochemical Assessment of Advanced Glycation End Products in the Human Retina and Optic Nerve Head
Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1201 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. E. de Gooyer, K. A. Stevenson, P. Humphries, D. A. C. Simpson, T. A. Gardiner, and A. W. Stitt
Retinopathy Is Reduced during Experimental Diabetes in a Mouse Model of Outer Retinal Degeneration
Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5561 - 5568.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Hall
Review of the Pericyte during Angiogenesis and its Role in Cancer and Diabetic Retinopathy
Toxicol Pathol, October 1, 2006; 34(6): 763 - 775.
[Full Text] [PDF]

Home page
 CirculationHome page
A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Circulation, August 8, 2006; 114(6): 597 - 605.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Shoji, H. Koyama, T. Morioka, S. Tanaka, A. Kizu, K. Motoyama, K. Mori, S. Fukumoto, A. Shioi, N. Shimogaito, et al.
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Diabetes, August 1, 2006; 55(8): 2245 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A Lecleire-Collet, L H Tessier, P Massin, V Forster, G Brasseur, J A Sahel, and S Picaud
Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants
Br. J. Ophthalmol., December 1, 2005; 89(12): 1631 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group
Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes
Diabetes, November 1, 2005; 54(11): 3103 - 3111.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. C. Thomas, C. Tikellis, W. M. Burns, K. Bialkowski, Z. Cao, M. T. Coughlan, K. Jandeleit-Dahm, M. E. Cooper, and J. M. Forbes
Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2976 - 2984.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
G. R. Barile, S. I. Pachydaki, S. R. Tari, S. E. Lee, C. M. Donmoyer, W. Ma, L. L. Rong, L. G. Buciarelli, T. Wendt, H. Horig, et al.
The RAGE Axis in Early Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2916 - 2924.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Jaleel, P. Halvatsiotis, B. Williamson, P. Juhasz, S. Martin, and K. S. Nair
Identification of Amadori-Modified Plasma Proteins in Type 2 Diabetes and the Effect of Short-Term Intensive Insulin Treatment
Diabetes Care, March 1, 2005; 28(3): 645 - 652.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. W. Stitt, C. McGoldrick, A. Rice-McCaldin, D. R. McCance, J. V. Glenn, D. K. Hsu, F.-T. Liu, S. R. Thorpe, and T. A. Gardiner
Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3
Diabetes, March 1, 2005; 54(3): 785 - 794.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. T. Mustata, M. Rosca, K. M. Biemel, O. Reihl, M. A. Smith, A. Viswanathan, C. Strauch, Y. Du, J. Tang, T. S. Kern, et al.
Paradoxical Effects of Green Tea (Camellia Sinensis) and Antioxidant Vitamins in Diabetic Rats: Improved Retinopathy and Renal Mitochondrial Defects but Deterioration of Collagen Matrix Glycoxidation and Cross-Linking
Diabetes, February 1, 2005; 54(2): 517 - 526.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Nakamura and T. Niwa
Pyridoxal Phosphate and Hepatocyte Growth Factor Prevent Dialysate-Induced Peritoneal Damage
J. Am. Soc. Nephrol., January 1, 2005; 16(1): 144 - 150.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. A. Kowluru and S. Odenbach
Effect of Long-Term Administration of {alpha}-Lipoic Acid on Retinal Capillary Cell Death and the Development of Retinopathy in Diabetic Rats
Diabetes, December 1, 2004; 53(12): 3233 - 3238.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J.-L. Wautier and A. M. Schmidt
Protein Glycation: A Firm Link to Endothelial Cell Dysfunction
Circ. Res., August 6, 2004; 95(3): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
B. Liu, M. Bhat, A. K. Padival, D. G. Smith, and R. H. Nagaraj
Effect of Dicarbonyl Modification of Fibronectin on Retinal Capillary Pericytes
Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1983 - 1995.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. C. Mamputu and G. Renier
Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants
J. Leukoc. Biol., June 1, 2004; 75(6): 1062 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. A. Voziyan, R. G. Khalifah, C. Thibaudeau, A. Yildiz, J. Jacob, A. S. Serianni, and B. G. Hudson
Modification of Proteins In Vitro by Physiological Levels of Glucose: PYRIDOXAMINE INHIBITS CONVERSION OF AMADORI INTERMEDIATE TO ADVANCED GLYCATION END-PRODUCTS THROUGH BINDING OF REDOX METAL IONS
J. Biol. Chem., November 21, 2003; 278(47): 46616 - 46624.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. O. Metz, N. L. Alderson, M. E. Chachich, S. R. Thorpe, and J. W. Baynes
Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in Vivo: EVIDENCE ON THE ROLE OF LIPIDS IN CHEMICAL MODIFICATION OF PROTEIN AND DEVELOPMENT OF DIABETIC COMPLICATIONS
J. Biol. Chem., October 24, 2003; 278(43): 42012 - 42019.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
F. Schutt, M. Bergmann, F. G. Holz, and J. Kopitz
Proteins Modified by Malondialdehyde, 4-Hydroxynonenal, or Advanced Glycation End Products in Lipofuscin of Human Retinal Pigment Epithelium
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3663 - 3668.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. Wendt, N. Tanji, J. Guo, B. I. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. P. Nawroth, S. F. Yan, V. D'Agati, et al.
Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy
J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1383 - 1395.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.